Moleculin Biotech公司:首个“奇迹”试验揭盲预计在2026年第一季度;全球试验现已覆盖九个国家

美股速递
Jan 12

Moleculin Biotech公司宣布,其备受瞩目的“奇迹”临床试验的首次揭盲时间预计将落在2026年第一季度。这项具有突破性意义的全球试验,目前参与范围已显著扩大,现覆盖全球九个国家的临床中心,标志着该疗法在跨国研究合作中迈出关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10